Terence Kin Wah Lee

Title: Terence Kin Wah Lee: Innovator in Cancer Treatment

Introduction

Terence Kin Wah Lee is a prominent inventor based in Hong Kong, CN. He has made significant contributions to the field of cancer treatment through his innovative research and inventions. With a total of 3 patents, Lee is recognized for his work in the diagnosis and treatment of cancerous diseases.

Latest Patents

One of his latest patents is focused on the cytotoxicity mediation of cells evidencing surface expression of CD44. This invention relates to the diagnosis and treatment of cancerous diseases, particularly the mediation of cytotoxicity of primary and metastatic human tumor cells. It emphasizes the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, to initiate the cytotoxic response in human tumors. This includes any primary or metastatic tumor sites that arise from hepatocytes. The invention also encompasses binding assays that utilize the CDMAB.

Career Highlights

Terence Kin Wah Lee is currently associated with Hoffmann-La Roche Inc., where he continues to advance his research in cancer treatment. His work has garnered attention for its potential impact on improving therapeutic strategies for cancer patients.

Collaborations

Some of his notable coworkers include David S F Young and Daad Sayegh, who contribute to the collaborative efforts in their research endeavors.

Conclusion

Terence Kin Wah Lee's innovative work in cancer treatment exemplifies the importance of research and development in the medical field. His contributions through patents and collaborations highlight his commitment to advancing healthcare solutions.